TW200510429A - Heterocyclic MCHR1 antagonists - Google Patents

Heterocyclic MCHR1 antagonists

Info

Publication number
TW200510429A
TW200510429A TW093109839A TW93109839A TW200510429A TW 200510429 A TW200510429 A TW 200510429A TW 093109839 A TW093109839 A TW 093109839A TW 93109839 A TW93109839 A TW 93109839A TW 200510429 A TW200510429 A TW 200510429A
Authority
TW
Taiwan
Prior art keywords
heterocyclic
mchr1 antagonists
mchr1
antagonists
11cby
Prior art date
Application number
TW093109839A
Other languages
English (en)
Chinese (zh)
Inventor
Kevin K Barvian
Andrew J Carpenter
Joel P Cooper
Paul L Feldman
Dulce M Garrido
Guo Yuc
Anthony L Handlon
Donald L Hertzog
Clifton E Hyman
Andrew J Peat
Gregory E Peckham
Jason D Speake
William R Swain
Francis X Tavares
Huiqiang Zhou
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of TW200510429A publication Critical patent/TW200510429A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW093109839A 2003-04-11 2004-04-09 Heterocyclic MCHR1 antagonists TW200510429A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46229203P 2003-04-11 2003-04-11

Publications (1)

Publication Number Publication Date
TW200510429A true TW200510429A (en) 2005-03-16

Family

ID=33299933

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093109839A TW200510429A (en) 2003-04-11 2004-04-09 Heterocyclic MCHR1 antagonists

Country Status (8)

Country Link
US (1) US20060194871A1 (https=)
EP (1) EP1618112A1 (https=)
JP (1) JP2006522812A (https=)
AR (1) AR044011A1 (https=)
CA (1) CA2521832A1 (https=)
MX (1) MXPA05010859A (https=)
TW (1) TW200510429A (https=)
WO (1) WO2004092181A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989445B2 (en) 2005-04-28 2011-08-02 Takeda Pharmaceutical Company Limited Thienopyrimidone compound
WO2007011285A1 (en) * 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
WO2007035935A1 (en) * 2005-09-23 2007-03-29 Coley Pharmaceutical Group, Inc. METHOD FOR 1H-IMIDAZO[4,5-c]PYRIDINES AND ANALOGS THEREOF
CN101273026A (zh) 2005-09-30 2008-09-24 霍夫曼-拉罗奇有限公司 作为mch受体拮抗剂的茚满衍生物
US8618115B2 (en) * 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7745447B2 (en) * 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
KR20080094699A (ko) * 2006-02-15 2008-10-23 사노피-아벤티스 신규 아미노알콜-치환된 아릴디하이드로이소퀴놀리논, 이의제조 방법 및 이의 약물로서의 용도
EP1987020B1 (en) * 2006-02-15 2012-10-03 Sanofi Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
JP5225269B2 (ja) * 2006-06-08 2013-07-03 イーライ リリー アンド カンパニー 新規なｍｃｈ受容体アンタゴニスト
MX2008015662A (es) * 2006-06-08 2009-01-12 Lilly Co Eli Nuevos receptores antagonistas de la hormona concentradora de melanina (mch).
US20070299062A1 (en) * 2006-06-26 2007-12-27 The Procter & Gamble Company Melanin concentrating hormone antagonists
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
WO2008020799A1 (en) 2006-08-18 2008-02-21 Astrazeneca Ab Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists
EP2121654A1 (en) 2007-01-10 2009-11-25 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
US8198307B2 (en) * 2007-05-11 2012-06-12 Korea Research Institute Of Chemical Technology Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same
KR20100044225A (ko) 2007-07-21 2010-04-29 알바니 몰레큘라 리써치, 인크. 5-피리디논 치환된 인다졸
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
TW201040153A (en) 2009-02-13 2010-11-16 Sanofi Aventis Novel substituted tetrahydronaphthalenes, process for preparation thereof and use thereof as medicaments
UY32442A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
EP2848621A4 (en) * 2012-05-10 2016-06-01 Takeda Pharmaceutical AROMATIC RING CONNECTION
KR101551313B1 (ko) * 2014-07-28 2015-09-09 충남대학교산학협력단 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
JP6785217B2 (ja) * 2014-07-31 2020-11-18 インスティチュート パスツール コリア ２−アミノ−ベンゾイミダゾール誘導体ならびにこれらの５−リポキシゲナーゼおよび／またはプロスタグランジンｅシンターゼ阻害剤としての使用
CN106866545B (zh) * 2017-03-31 2019-07-09 枣庄学院 1-环烷烃-5-硝基-1h-苯并[d]咪唑类化合物及其制备方法
CN107445899A (zh) * 2017-07-19 2017-12-08 枣庄学院 一种苯并咪唑类化合物及其制备方法
CN109020895B (zh) * 2018-08-07 2020-04-24 枣庄学院 一种金属催化的1-苄胺基取代苯并咪唑的合成方法
WO2021207530A1 (en) * 2020-04-08 2021-10-14 Remix Therapeutics Inc. Compounds and methods for modulating splicing

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1285651B1 (en) * 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonists
EP1299362A4 (en) * 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
AR044011A1 (es) 2005-08-24
WO2004092181A1 (en) 2004-10-28
JP2006522812A (ja) 2006-10-05
EP1618112A1 (en) 2006-01-25
US20060194871A1 (en) 2006-08-31
CA2521832A1 (en) 2004-10-28
MXPA05010859A (es) 2005-12-14
WO2004092181A9 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
TW200510429A (en) Heterocyclic MCHR1 antagonists
UA83659C2 (ru) Антагонисты рецепторов p2x7 и их применение, фармацевтическая композиция на их основе, способ их получения (варианты)
MXPA05010137A (es) Derivados de tetrahidroisoquinolil acetamida para usarse como antagonistas del receptor de orexina.
MY122392A (en) Adamantane derivatives of use of p2x7 receptor antagonists, a process for their preparation, pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
MY137535A (en) New pyrrolidinium derivatives
ATE300533T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate als urotensin ii rezeptor-antagonisten
TW200613243A (en) Novel compounds
IL150085A0 (en) New-p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
MXPA04000707A (es) Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
IL177291A0 (en) Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
MX2007008614A (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
MY143581A (en) Carboxamide derivatives as muscarinic receptor antagonists
ZA200500951B (en) Azabicyclo derivatives as muscarinic receptor antagonists
MX2007010414A (es) Derivados de piridin-2-carboxamida como antagonistas de mglur5.
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
EA200701324A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
ATE352543T1 (de) Ein dioxino(2,3-g)chinolin-9-carbonsäure derivat als nk3 rezeptor antagonist
MXPA05011243A (es) Benzopiranos substituidos como agonistas selectivos del receptor beta de estrogeno.
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
PT1673354E (pt) Arilindenopiridinas e arilindenopirimidinas e sua utilização como antagonistas do receptor da adenosina a2a
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação
WO2001029066A3 (en) Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them